A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

Inclusion Criteria Concurrent Medication: Allowed: * Antipyretics for rectal temperature \>= 100.4 F. * Antiretroviral therapy. Patients must have: * HIV positivity. * Birth weight at least 1800 g (3.75 lb). * Consent and compliance of parent or guardian. NOTE: * Coenrollment in other therapeutic protocols (except ACTG 218, 230, and 279) is permitted. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Enrollment in HIV vaccine trials. * Major congenital anomalies that are incapacitating, result in immunologic abnormalities, or require major surgical procedures. * Congenital immunoglobulin deficiency, SS or SC hemoglobinopathy, or asplenia. * Hypogammaglobulinemia. Concurrent Medication: Excluded: * Prophylactic antipyretics. Patients with the following prior conditions are excluded: Acute moderate to severe intercurrent illness or fever within 72 hours prior to study entry. Prior Medication: Excluded: * Any prior pneumococcal vaccine. * Measles vaccine within 1 month prior to study vaccination. * Any other routine vaccine within 1 week prior to study vaccination. * Any immunosuppressant agent, including prednisone, for more than 6 weeks. Prior Treatment: Excluded: * Blood products within 56 days prior to study vaccination.